Benitec Biopharma (BNTC) FCF Margin (2019 - 2023)

Benitec Biopharma (BNTC) reported FCF Margin of 58342.86% for Q2 2023, down 684.3% sequentially from 7438.89% in Q1 2023.

Benitec Biopharma (BNTC) FCF Margin (2019 - 2023) Analysis & Trends

Benitec Biopharma (BNTC) has 5 years of FCF Margin data on file, last reported at 58342.86% in Q2 2023.

For the quarter ending Q2 2023, FCF Margin changed N/A year-over-year to 58342.86%; the trailing twelve-month figure through Mar 2024 stood at 288485.71% (down 26079454.0% YoY), and the FY2023 full-year result was 24001.33%, down 220270.0% from the prior year.
FCF Margin eased to 58342.86% in Q2 2023, from 7438.89% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 9022.86% in Q2 2020 to a low of 346000.0% in Q4 2020.
A 5-year average of 71471.89% and a median of 7438.89% in 2023 frame the typical range for FCF Margin.
Across the five-year window, FCF Margin slumped 34200519 bps in 2020 and jumped 33280000 bps in 2021, its largest moves.
Tracing BNTC's FCF Margin over 5 years: stood at 3994.81% in 2019, then slumped by 8561 bps to 346000.0% in 2020, then surged by 96 bps to 13200.0% in 2021, then slumped by 217 bps to 41821.43% in 2022, then sank by 40 bps to 58342.86% in 2023.
Business Quant data shows BNTC's FCF Margin at 58342.86% in Q2 2023, 7438.89% in Q1 2023, and 41821.43% in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Benitec Biopharma	46.45 Mn	46.45 Mn	-	-

Download Data